Abbott to buy Chile’s CFR for $3bn


US medical products specialist Abbott has agreed to buy Chilean generic drugmaker CFR Pharmaceuticals for $2.9 billion (£1.7 billion), and will take on $430 million of CFR’s debt.

The move will bolster Abbott’s position in the rapidly growing markets of Latin America, expanding the company by around 7000 employees at R&D and manufacturing facilities in Chile, Colombia, Peru and Argentina. Abbott will also get access to CFR’s portfolio of over 1000 branded generic drugs and other products, as well as its distribution networks across the region.


Related Content

Abbot boosts heart devices with St Jude buyout

6 May 2016 Business

news image

Medical devices consolidation continues with $25bn deal, but Abbott expresses concerns over proposed Alere merger

Medical devices consolidation continues

4 February 2016 Business

news image

Abbott to buy Alere for $5.8bn to augment its point-of-care diagnostics business

Most Commented

Ethanol to butanol conversion shows sustainable potential

13 January 2016 Research

news image

Borrowed hydrogen chemistry drives reaction to obtain useful fuel from biomass

Injectable foam repairs bones

22 December 2015 Research

news image

Scientists say biomaterial could treat bone defects and diseases